Evidence map›Paper›PMID 42216979›Full record

ArticleDiscover oncology2026

Low initial hemoglobin and high-risk additional chromosomal abnormalities predict poor long-term survival in chronic phase chronic myeloid leukemia.

Qingyuan Wang, Yucheng Jiang, Xiangyu Zhao, Yiyan Zhu, Zhao Zeng, Xiaofei Yang, Qian Wu, Jinlan Pan, Li Yao, Jiannong Cen and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Qingyuan Wang *National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Yucheng Jiang *National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Xiangyu Zhao *National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Yiyan Zhu *National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Zhao ZengNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Xiaofei YangNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Qian WuNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Jinlan PanNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Li YaoNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Jiannong CenNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Suning ChenNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China. chensuning@suda.edu.cn.
Mengxing XueNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China. xuemengxing@suda.edu.cn.

Funding

National Natural Science Foundation of China 82200150
6 · The paper itself

Abstract

Predicting prognosis using baseline clinical and genetic features remains critical in the tyrosine-kinase-inhibitor (TKI) era of chronic myeloid leukemia (CML). We retrospectively analyzed 944 chronic phase CML (CML-CP) patients treated at a single center in China, aiming to clarify treatment responses, long-term outcomes and baseline prognostic factors in real-world settings. Analyses were performed in available patient subsets depending on endpoint-specific data completeness. The study found that female patients had higher major molecular response (MMR) than males (P = 0.004). Age ≥ 45 years was associated with lower complete cytogenetic response (CCyR; p = 0.006), overall survival (OS; p = 0.011), and CML-related survival (p = 0.010). Initial white-blood-cell counts ≥ 118 × 10⁹/L predicted inferior CCyR and MMR (both P < 0.001). Conversely, baseline haemoglobin ≥ 110 g/L independently predicted superior CCyR, MMR (both P < 0.001), event-free survival (EFS; p = 0.009), progression-free survival (PFS; p = 0.008), OS (P = 0.001), and CML-related survival (p = 0.001). Compared to patients without ACAs, high-risk additional chromosomal abnormalities (HR-ACAs) conferred worse EFS (P = 0.042), PFS (P = 0.057), OS (P = 0.010) and CML-related survival (P = 0.006). Gender and initial WBC primarily influenced TKI treatment responses, while age and initial Hgb levels influenced both TKI responses and long-term survival. Additionally, HR-ACAs significantly predicted poorer long-term survival in CML-CP patients.

Indexed as

Chronic myeloid leukemiaHR-ACAsInitial hemoglobin

Identifiers

PMID42216979
PMCPMC13433872

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.